Oxeia Biopharmaceuticals, Inc. (OXEA)
Oxeia Biopharmaceuticals is a clinical-stage biotech company developing new, innovative therapies for conditions that are defined by deficits in neurocognition from injury, degeneration and aging.
Our first two indications are for (i) mild traumatic brain injury, known as concussion, and (ii) the cognitive decline, lethargy and “brain-fog” associated with Covid-19 infection, known as Covid Longhauler syndrome (“Long Covid”).
On May 1, 2017, we acquired certain rights to a ghrelin molecule OXE103 that was originally developed by Daiichi Sankyo for non-neurologic indications.
OXE103 has not been approved by the FDA for any non-neurological indications. The license provides access to an open FDA IND containing full preclinical safety data as well as safety data from three human Phase I studies, four multi-dose human Phase II studies, and one Phase III study.
We are currently conducting a Phase 2 study under an FDA approved IND at the University of Kansas Medical Center in two concussion populations.
|CEO||Dr. Michael Wyand|
361 Newbury Street, Suite 500
Boston, MA 02115
|Fiscal Year||January - December|
|Dr. Michael Wyand||Chief Executive Officer|
|Kartik Shah||Director and Co-Founder|
|Julianne Averill||Chief Financial Officer|
|Dr. Vishal Bansal||Chief Science Officer and Co-Founder|
Latest SEC Filings
|Jun 8, 2022||RW||Filing|
|May 3, 2022||FWP||Free Writing Prospectus|
|Apr 14, 2022||S-1||General form for registration of securities under the Securities Act of 1933|
|Jan 27, 2022||DRS/A||[Amend] [Cover] Draft Registration Statement|
|Dec 8, 2021||DRS||[Cover] Draft Registration Statement|
|Jun 16, 2014||D||Notice of Exempt Offering of Securities|